Recently, Xu et al. developed CAR-T cells containing monoclonal antibodies specific to IL-13Rα2 receptors present in GBM . We hypothesize that to be a GBM-specific CAR T-cell, the CAR should bind to a specific binding region of the IL-13Rα2 receptor. These CAR T-cells have shown anti-GBM efficacy and could be a potential candidate for GBM treatment.